BioCentury
ARTICLE | Product Development

Ready for PRIME time

Biogen gambles that aducanumab Phase 1b can define the therapeutic window

March 30, 2015 7:00 AM UTC

If interim data on cognition that Biogen Inc. reported for aducanumab in Alzheimer's disease hold up, the risk of jumping directly from Phase Ib to Phase III testing will be more than worth it. The data, from exploratory endpoints in the Phase Ib PRIME study, are among the best ever reported for an anti-beta amyloid antibody to treat AD.

Charles DeCarli, a professor of neurology at the University of California Davis, said if the magnitude of the apparent benefit held up over the course of a patient's illness, it would double the amount of time that patients remained functionally independent...